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license (http://creativecommons.org/Abstract Objective: To conduct a systematic review and meta-analysis to summarize evi-
dence and determine the impact of coronary revascularization (CR) on cardiac patients’
Health-Related Quality of Life (HRQoL), highlighting factors that may affect this outcome in
patients.
Methods: A systematic search of Medline (Pubmed), EMBASE, Cochrane Library, Sciverse (Sci-
ence Direct and Scopus) and PsycInfo was conducted to identify studies published from January
2000 to December 2012. Data were analyzed using MIX 2.0 Pro and SPSS 20.
Results: Thirty-four longitudinal studies met the inclusion criteria; these studies included
15,992 patients, of whom 8,027 had undergone PCI, 6,348 had undergone CABG and 1,617
had received medication treatment. Moderate long-term effect sizes were revealed for both
CR procedures. Both percutaneous coronary interventions (PCI) and coronary artery bypass
graft surgery (CABG) had significantly greater effects on HRQoL than did medication; however,
the CR procedures did not differ significantly from each other. Moderators included the type of
instrument used to assess HRQoL and the study quality. Benefits related to physical functioning
were greater than those related to psychosocial functioning in patients treated with CABG.ousi, Department of Psychology, Health & Human Sciences Research Institute, University of
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224 M.G. Takousi et al.Conclusions: Empirical research highlights the positive effect of CR on patient HRQoL. Re-
searchers should carefully select the instrument they use to measure HRQoL, as this may affect
the results and thus conclusions. More RCTs and between-group studies employing pre-post de-
signs should be conducted before clear conclusions can be drawn.
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4.0/).1. Introduction
The field of coronary heart disease has advanced consid-
erably in the last decade. Through the use of interventional
(percutaneous coronary interventions; PCI) and surgical
(coronary artery bypass graft surgery; CABG) procedures,
symptom relief and survival rates have increased globally.1
The comparative effectiveness of CABG versus PCI in
patients who are eligible for either procedure is poorly
understood,2 although a recent review suggested that older
patients and patients with diabetes treated with CABG had
increased survival rates relative to patients treated with
PCI.3
In addition to survival and symptom relief, health-
related quality of life (HRQoL) among patients with car-
diovascular disease is a critical issue.4 Based on the World
Health Organization’s definition, health is not only a
biomedical but also a biopsychosocial issue.5 Although no
consensus definition exists, HRQoL includes physical, psy-
chological and social well-being.6,7 Enhancing coronary
patients’ HRQoL should be a component of the priorities of
a medical team.
Few systematic reviews over the past ten years have
examined the effect of coronary interventions on HRQoL.
Jokinen and colleagues8 reviewed 21 randomized control
trials (RCT) evaluating CABG and concluded that post-
surgical patients experienced improved HRQoL regardless
of which procedure they had undergone (On- vs Off-Pump
CABG), especially when the procedure was performed by
experienced surgeons. Furthermore, the results of a RCT
conducted by Jokinen and colleagues (2010) suggested that
preoperative HRQoL predicted posttreatment HRQoL, with
long-lasting beneficial effects and HRQoL increasing to a
level comparable to that of the general population post-
treatment. Noyez et al. (2011)9 reviewed 29 articles
addressing the effects of cardiac surgery. They concluded
that many studies had presented only postoperative QoL
data, which limited the derivation of conclusions concern-
ing the beneficial effect of heart surgery on QoL. They also
highlighted the need for good clinical trials with longer
follow-up periods (periods greater than one year). Sun
et al. (2012)10 and Cormack et al. (2012)11 reviewed 13 RCTs
and 28 longitudinal studies, respectively, that had investi-
gated CABG. Both reviews concluded that CABG patients
may experience a decline in cognitive functioning during
the weeks immediately following treatment but that this
decline reversed at twelve months postsurgery. Finally,
Blankenship et al.12 reviewed 25 studies and concluded that
the effect of PCI on QoL was greater than that of medical
(drug) treatment; however, this benefit decreased overtime. Moreover, the effect of PCI on QoL during the month
immediately following treatment was greater than that of
CABG; however, in the long-term, both procedures lead to
similar improvements in QoL. Blankenship et al.12 also
suggested that patients of all ages benefited equally
regardless of which revascularization procedure was per-
formed, although they found that women reported lower
HRQoL than men following PCI. Unemployment status,
smoking and medical comorbidities were associated with
lower QoL following PCI.12
Soo Hoo et al. (2014)13 reviewed 18 studies of PCI and
supported Blankenship et al.’s (2013)12 conclusion that all
individuals, regardless of age, reported improvements in
HRQoL and that age, therefore, could not be considered as
a moderator, especially when other comorbidities were
taken into consideration.
Abah and colleagues (2015)14 reviewed 44 mostly retro-
spective studies on the influence of heart surgery (CABG,
PCI, Valve) on HRQoL on older patients. The results showed
that the majority of patients demonstrated improvement,
while 8-19% demonstrated a decline, in HRQoL following
heart surgery.
Although these reviews may provide insights into the
effect of CR on HRQoL in cardiac patients, a number of
issues need to be addressed prior to making recommenda-
tions for clinical practice. For instance, Sun et al. (2012)10
and Cormack et al. (2012)11 focused only on one aspect of
HRQoL, cognitive functioning; thus, a clear conclusion
about the effect of CR on other aspects of HRQoL cannot be
drawn. Blankenship et al.’s (2012)12 study, while of good
quality, was solely a literature review and lacked rigorous
systematic methodology (e.g., many studies included were
of low quality and/or provided only posttreatment data for
the effect of CR on HRQoL); thus, conclusions from this
study may be biased. Noyez et al.’s (2011)9 and Abah
et al.’s (2015)14 work focused on surgical treatment of
various heart problems (e.g., aortic or mitral valve surgery)
instead of only on treatment of coronary artery disease.
Hence, further investigations are needed to establish clear
conclusions regarding the effect of CR on HRQoL. Finally, no
prior reviews have provided effect sizes for the association
between CR on HRQoL, as they did not use meta-analytic
techniques to illustrate the extent of the effect of CR and
its moderators. Thus, a systematic review and meta-
analysis was needed update the literature and, due to the
nature of these methodologies, simultaneously provide a
more complete understanding of the impact of CR and its
potential moderators on HRQoL.
The main aim of the present systematic review was to
determine the impact of CR on HRQoL and identify factors
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Figure 1 Flow diagram for selection of studies.
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develop recommendations for both future research and
clinical practice. The objectives of this study were as fol-
lows: a) to estimate the size of the overall effect of coro-
nary revascularization on HRQoL in patients, b) to detect
any differences in the effects of two types of CR (PCI and
CABG) on HRQoL, and c) to identify factors moderating
HRQoL following coronary revascularization.
2. Methods
The methodology used in the present study followed the
Centre for Reviews and Dissemination15 guidance for sys-
tematic reviews and the Cochrane Collaboration16 and Field
and Gillett’s17 suggestions for systematic reviews with
meta-analysis.
2.1. Systematic literature search
The literature search was conducted from December 2012
to January 2013 using five online databases: Medline
(Pubmed), EMBASE, Cochrane Library, Sciverse (Science
Direct and Scopus) and PsycInfo. Keywords used in all
searches were “quality of life (QoL) or health-related
quality of life (HRQoL) or health status and heart surgery
or coronary bypass or CABG or PCI or PTCA or coronary
angioplasty or coronary percutaneous interventions not
adolescent not children”. Terms were searched for in the
titles, abstracts and keywords. The search included studies
published in the 13-year period from January 2000 to
December 2012. In addition, “snowball” techniques18 were
used; through this technique, reference lists of primary
studies and reviews were searched manually to detect
studies that may fulfil inclusion criteria. Abstracts written
in English were also considered, even if the research paper
was written in another language. When an abstract seemed
relevant to the topic under investigation and the paper was
published in a language other than English, Greek, French,
German, and Spanish, the authors were contacted to
determine whether a full English version or results section
were available. Authors were also contacted when their
papers seemed eligible for inclusion but not all information
needed for the analysis was presented.
Studies were included if they fulfilled the following
criteria: (1) participants should be 19 years of age; (2)
HRQoL was the target outcome; (3) study design was ran-
domized, non-randomized or observational; (4) at least two
interval times were reported, including pretreatment
(baseline) and postoperation; (5) data were collected after
1996; (6) published in a peer-reviewed journal; and (7)
published in various languages at which the present authors
were proficient (i.e., English, Greek, French, Spanish, and
German).
A cut-off point of 1996 was selected to reduce hetero-
geneity in outcomes resulting from “old” medical proced-
ures not commonly used today. According to the cardiology
literature, in the last fifteen years, new methods have been
developed for both interventional and surgical coronary
revascularization.19,20
Studies were excluded when (1) they used a question-
naire that did not measure all subdomains of HRQoL (basedon the WHO definition) or that had poor/unknown psycho-
metric properties, (2) they used a qualitative or case study
design, (3) available data were not sufficient for effect size
estimation even after contacting the corresponding author,
(4) only norm-based summary scores were presented and
(5) they were psychometric studies testing the properties of
a QoL instrument.
2.2. Screening identified studies
A total of 1123 citations were identified in the initial
searches. Details about the exclusion procedure are shown
in the flow diagram below (Figure 1).
In total, 34 papers fulfilled the criteria for inclusion in
this review. Of these, 29 were written in English, 2 in
German, 2 in Spanish and 1 in Greek.
2.3. Data extraction
Studies were coded for the following: year of publication;
country; type of CR; study design; sample size at baseline
and follow-up(s); mean age; sex distribution; smoking sta-
tus; body mass index (BMI); diagnosis of hypertension;
diagnosis of diabetes (I or II); intervention duration; num-
ber of follow-up assessments; QoL measurement tool; data
collection method (e.g., face-to-face, email, or phone);
pre- and post-intervention QoL score (raw mean score for
226 M.G. Takousi et al.each subscale at baseline and last follow up and their
standard deviations or mean difference, confidence in-
tervals (CI), standard error (SE), and p values); effect size
(when provided); and the authors’ main findings. An SPSS
data sheet was created for each included study to facilitate
d conversions and avoid hand calculation errors.
2.4. Studies’ quality assessment
Studies were assessed for quality using a combination of the
Downs and Black21 checklist for methodological quality
(examining reporting, external validity, and bias); Noyez
et al.’s9 requirements for a ‘good’ study; and the Critical
Appraisal Skills Programme22 instrument for assessing the
overall quality of cohort studies. Ten total criteria were
applied: (Does the study address a clearly defined issue? Are
patient characteristics clearly described? Were the main
outcome measures used accurate (valid, reliable and
disease-specific)? Were confounding factors taken into
consideration? Have the characteristics of patients lost to
follow-up been described? Were losses of patients to
follow-up taken into account? Is the procedure described?
Were the statistical tests used to assess the main outcomes
appropriate? Are the main findings of the study clearly
described? Was the follow-up period sufficiently long (i.e.,
> 12 months)?). Studies were scored 0 when a criterion was
not met, 0.5 when a criterion was partially met and 1 when
a criterion was totally met. Scores could, therefore, range
from 0 to 10.
2.5. Analysis
Standardized mean differences (SMDs) were generated to
estimate effect sizes (ESs) for each study in accordance
with recommended guidelines.17,23 For within group anal-
ysis of pre-and post-intervention HRQoL scores, d indicated
the difference between the mean pre- and post-test scores
divided by the pre-test standard deviation. For between
group comparisons, d indicated the average change in one
group before and after the intervention minus the mean
change of the other group divided by the pre-intervention
pooled standard deviation.24e26 ESs were corrected for
biases due to small sample size using Hedges’ g index.26
Similar to Cohens’ d, Hedges’ g pools standard deviations
assuming equal population variances. However, unlike d, g
factors n-1 instead of n into the pooling, and therefore
provides a better estimation, especially when sample size is
small. The overall effect size was estimated both with
fixed-effects models (assuming one true effect and any
variation is due to random error) and random-effects
models (assuming that there is not one true effect due to
variations among studies as each study represents a
“unique” population). The random-effects model was
selected for subgroup analyses due to the assumption that
individual studies estimated different effects. Homogenei-
ty analyses of ES variances were conducted using Q, I2 and
t2 statistics. The Q index represented the weighted sum of
the squared differences between the studies’ means and
fixed-effect estimations; however, it could be influenced by
the number of studies included. When Q was significant,
heterogeneity was assumed. I2 measured the heterogeneitybased on the Q index taking into account sample sizes. I2
values of 0-40 indicated no important heterogeneity, while
a value of approximately 50 indicated medium and
approximately 75 indicated considerable heterogeneity. t2
assessed the between study variances without being influ-
enced by the number of studies included in the analyses.
When t2> 1, then substantial heterogeneity is assumed.
Potential publication biases were examined using Begg’s z
(rank correlation between standardized effect size and the
variance of these effects) and Egger’s t indices27 (Egger’s t
is similar to Begg’s z but uses the values of effects sizes and
their variances rather than their ranks). Sensitivity analyses
was conducted by excluding outliers and poorer quality
studies.28 Analyses were performed using MIX 2.0 Pro,29,30
Excel (MS office Excel, 2007) and SPSS 20.31
3. Results
Of the 34 studies identified, 8 evaluated the effects of only
PCI, 20 evaluated the effects of only CABG and 6 evaluated
the effects of both PCI and CABG on HRQoL. Therefore, 14
studies examined PCI, and 26 studies examined CABG. The
majority of studies (kZ 26) had a moderate to good qual-
ity, ranging from 5 to 7.5 points, while a few studies (kZ 8)
had a low quality, ranging from 3.5 to 4.5 points.
In total, 15,992 patients were included in these studies
(8,027 had undergone PCI, 6,348 had undergone CABG and
1,617 had received medication treatment). Patient de-
mographic and clinical characteristics for each study are
summarized in Table 1. Among these patients, mean age
was 63.0 years (SDZ 4.2) and, on average, samples were
23% female and 32% smokers, with 59% of the patients
having hypertension and 24% of the patients having dia-
betes (see Table 1).
The majority of studies (kZ 22) used the SF-36 for
measuring HRQoL. Other measurements of Quality of Life
used were SAQ (kZ 2), NHP (kZ 3), Rand-36 (kZ 1),
WHOQoL (kZ 1), MacNew (kZ 3), and EQ-5D (kZ 1).
Most studies (kZ 15) assessed HRQoL up to 1 year after
CR.32e47 Fourteen studies (kZ 14) had a shorter follow-up,
ranging from 1 to 6 months.48e60 and only five studies
(kZ 5) had a follow-up period longer than 12 months,
ranging from 24 to 96 months.61e65
Table 2 displays additional characteristics, such as
number of follow-ups and summaries of the main findings of
each study.
3.1. CR Overall Effect on HRQoL
The size of the overall effect on HRQoL after treatment is
displayed in Table 3. The relative contribution of each
study on the overall effect of coronary revascularization
(using random-effects assumptions) on patient HRQoL can
been observed in Figure 2. Analyses were conducted using
both random- and fixed-effects models, which suggested a
moderate to low improvement in HRQoL after all types of
treatments, even after controlling for length of follow up.
Univariate analysis of variances showed a significant dif-
ference between different treatment types [F(2,44)Z4.57,
p< .05]. Weighted multiple comparisons (Bonferroni post
hoc test) revealed that patients who underwent CABG or
Table 1 Baseline demographic and clinical characteristics of studies included in the review
Study (year) Country Sample size at
baseliney
Instrumentz Female % Mean age Smoking % Hypertension % Diabetes %
PCI CABG
1 Benzer (2003) Austria 64 33 MAcNew 35.3 64.5 44.3 NR NR
2 Cohen (2011) USA 903 897 SF-36 22.5 65.2 18.5/21.9 NR 38.1/28.9
3 Hofer (2006;2005) Austria 60 121 MAcNew 24.1 61.8 28.3/33.9 50/69.4 15/19.8
4 Lukkarinen (2006) Finland 100 100 NHP 32.5 57.2/61.8 4 NR NR
5 Skodova´ (2011) Slovakia 37 41 SF-36 15.1 55.8/59.4 NR NR NR
6 Zang (2003) Eur & Can. 488 500 SAQ 21 61.4 NR 45.2 14.4
7 de Quadros (2011) Brazil 110 SAQ 38 62.8 24 90 32
8 Denvir (2006) UK 1346 EQ-5D 32.5 60.9 38.6 32.5 11.1
9 Melberg (2010) Norway 427 SF-36 20.3 58.4 29.9 23.9 6.1
10 Li (2010;2012) China 287 SF-36 26.2 64 31 58 30
11 Viswanathan (2011) UK 2935 NHP 29.3 58.1 26.7 30.7 6.4
12 Weilu (2011) China 223 SF-36 14.3 60.6 51.6 52.9 13.9
13 Weintraub (2008) USA & Can. 969 RAND-36 15 62 29 67 34
14 Wong (2007) Hong Kong 78 SF-36 24.6 66 15.4 42.9 29.2
15 Azzopardi (2009) Australia 87 SF-36 14.6 66.6 24.2 97.9 42
16 Barolia (2012) Pakistan 65 WHOQOL-Brief 15.3 59.7 20.0 72.0 51.0
17 Colak (2008) Croatia 111 SF-36 12.6 61.1 NR 87 28.2
18 Damgaard (2011) Denmark 331 SF-36 11.8 59 46.5 47.6 25.3
19 Gjeilo (2008;2012) Norway 534 SF-36 22.7 NR NR NR NR
20 Houlind (2012) Denmark 900 SF-36 23.0 75 25.5 71.0 20.0
21 Hunt (2000) Australia 123 SF-36 22 64 NR NR NR
22 Jensen (2006) Denmark 120 SF-36 40 76 18.3 60.8 18.3
23 Kiebzak (2002) USA 85 SF-36 21.2 62 NR NR NR
24 Krecki, (2010) Poland 55 SF-36 25 61.5 36 96 49
25 Krannich (2007) Germany 142 SF-36 19.0 65.1 NR NR NR
26 Lie (2009) Norway 185 SF-36 10.3 62 29 NR 16.2
27 Martin (2012) USA 495 SF-12 17.1 63.9 44.0 78.0 32.0
28 Mathisen (2005) Norway 120 SF-36 21.6 64.4 NR 40 14.2
29 Merkouris (2009) Greece 63 MAcNew 23.8 72.9 64 62 35
30 Peric (2010; 2006) Serbia 243 NHP 20 58.7 43 70 19
31 Pfaffenberger (2010) German 55 SF-36 14.8 64.8 35.2 66.7 NR
32 Pirraglia (2003) USA 590 SF-36 28 65.1 68.3 52.4 25.6
33 Puskas (2004) USA 200 SF-36 22.5 62.3 29.4 63.8 33
34 Rothenha¨usler (2010) German 147 SF-36 16.5 60.8 NR NR NR
y baselineZ pre-revascularization.
z instrument used for ES calculations.
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Table 2 Additional characteristics and main findings of studies included in the review
ID Author QoL Focus N (prior to
treatment)
Study Design N (and duration) of
Follow-Ups
Main findings
Both interventions
1 Benzer, 2003 PCI vs CABG vs MED 64
33
109
Prospective, cross-
sectional
1 (12 m) Greater improvement in QoL 1 year after CABG
and PCI compared to medical therapy were
identified.
2 Cohen, 2011 PCI vs CABG 903
897
Prospective, cross-
sectional
3 (1 m, 6 m, 12 m) The PCI group scored higher on physical aspects
of QoL compared to the CABG group. NS
differences between treatment groups at were
observed at 12 months.
3 Hofer, 2006 PCI vs CABG vs MED 60
121
96
Prospective cross-
sectional
2 (1 m, 3 m) The CR groups demonstrated greater changes
in QoL compared to the MED groups. The PCI
group experienced a significant increase in QoL
1 month posttreatment, with a slight further
increase at 3 months. The CABG group
experienced a significant increase at 3 m.
Depression and anxiety scores accounted for
most of the change in HRQoL (64-69%), whereas
treatment accounted for less than 1% of the
changes in HRQoL at 3 m post treatment.
4 Lukkarinen, 2006 PCI vs CABG vs MED 100
100
80
Prospective, cross-
sectional
2 (12 m, 96 m) PCI & CABG pts had higher QoL after 12 and
96 m compared to MED patients.
CABG pts scored significantly better on
mobility, energy and pain. PCI pts had
significantly better HRQoL in emotional
reactions, pain, mobility and energy at 96 m
posttreatment.
5 Skodova´, 2011 PCI vs CABG vs MED 37
41
28
Prospective, cross-
sectional
2 (12 m, 24 m) Significantly better QoL was observed after all
types of treatment. The PCI and CABG groups
demonstrated significantly greater mean
changes in physical QoL aspects than the MED
group, while the CABG and MED groups
demonstrate significantly greater mean change
at mental QoL aspects.
6 Zang,2003 PCI vs CABG 488
500
Prospective, cross-
sectional
2 (6 m, 12 m) Both the CABG and PCI groups demonstrated
improvement in cardiac-related health status.
PCI interventions
7 de Quadros, 2011 PCI + pred 110 Prospective, repeated
measures
2 (6 m,12 m) Pts demonstrated a significant improvement
after treatment. Male gender and QoL at
baseline were significant predictors of
posttreatment QoL level.
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8 Denvir, 2006 PCI High vs low SES 1346 Prospective, repeated
measures
1 (12 m) Pts demonstrated a significant improvement
after treatment. Pts with low SES
demonstrated significantly lower mean HRQoL
scores at baseline and 12 m posttreatment
compared to those with high SES.
9 Melberg, 2010 PCI + non surg vs surg hospital 427 Prospective, repeated
measures
1 (6 m) Significant improvement of QoL after
treatment. Similar improvements observed in
both hospital types.
10 Li, 2012 PCI vs MED 287
298
Prospective, cross-
sectional
1 (6 m) PCI pts score higher in QOL 6 m posttreatment
compared to MED pts.
PCI elderly patients, especially those 80 years
of age, experienced the greatest benefit in QoL
6 m posttreatment.
11 Viswanathan, 2011 PCI with & without prior CABG 2935 Prospective, repeated
measures
3 (3 m, 12 m,
24 m)
Pts with previous CABG had less improvement
in HRQOL after PCI. At 24 m, patients with prior
CABG demonstrated worse physical functioning
than was reported at baseline.
12 Weilu, 2011 PCI stent effect 223 Prospective, repeated
measures
1 (6 m) At 6 m after intervention, HRQoL increased in
all 8 domains. Factors negatively associated
with 6 m QoL scores were as follows: gender,
age and activity were associated with bodily
pain; activity was associated with physical
functioning; and age and activity were
associated with mental health and general
health.
13 Weintraub, 2008 PCI vs MED 969
958
Prospective, cross-
sectional
7 (1 m, 3 m, 6 m,
12 m, 24 m, 36 m)
At 12 m posttreatment, pts that underwent PCI
demonstrated greater mean changes in HRQoL
compared to those receiving medication. At
36 m after treatment, NS differences between
groups existed.
14 Wong, 2007 PCI 78 Prospective, repeated
measures
2 (1 m, 3 m) Increased scores were observed after
treatment. NS changes in physical and social
functioning were identified.
CABG interventions
15 Azzopardi,2009 CABG 87 Prospective, repeated
measures
3 (6 m, 12 m,
24 m)
Increased scores at 24 m and NS differences
between pts and normative Australian
individuals were observed.
16 Barolia, 2011 CABG + gender & age dif 65 Prospective, repeated
measures
1 (1 m) Significant improvements in all domains were
observed. One m postsurgery, females had
significantly lower psychological health, while
patients >60 yrs of age had significantly
greater social satisfaction.
17 Colak, 2008 Cabg & comparison with norm 111 Prospective, repeated
measures
1 (12 m) Twelve m post treatment, pts demonstrated
improvements in all 6 domains of QoL. NS mean
changes in all subdomains were observed.
(continued on next page)
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Table 2 (continued )
ID Author QoL Focus N (prior to
treatment)
Study Design N (and duration) of
Follow-Ups
Main findings
18 Damgaard, 2011 CABQ vs CABG 170
161
Prospective, cross-
sectional
2 (3 m, 11 m) Significant improvements at 11 m
posttreatment and NS differences between the
two groups were observed.
19 Gjeilo, 2012 CABG + Gender & age effect 413 Prospective, repeated
measures
2 (6 m, 12 m) Female pts scored lower compared to male pts
at all measured time points. However, the
mean changes in most subscales favored
women (except the GH and ER scales). Pts 75
years of age demonstrated lower general
health and physical, social, role, and emotional
functioning compared to younger patients.
At 12 m posttreatment, pts had almost equal
HRQoL to non-cardiac populations with the
exception of role and physical functioning, on
which pts 75 years of age scored relatively
lower.
20 Houlind, 2012 CABG on vs off 900 Prospective, repeated
measures
1 (6 m) Pts demonstrated a significant improvement in
all domains. NS differences between groups
were observed.
21 Hunt, 2000 CABG 123 Prospective, repeated
measures
1 (12 m) Pts demonstrated a significant improvement.
NS gender differences were observed.
22 Jensen, 2006 CABG on vs off 120 Prospective, repeated
measures
1 (3 m) Pts demonstrated a significant improvement in
all domains. NS difference between groups
were observed.
23 Kiebzak, 2002 CABG 85 Prospective, repeated
measures
1 (12 m) Improvement at 1 yr and NS changes in role,
emotional and general health subscales were
observed.
24 Krannich, 2007 CABG 142 Prospective, repeated
measures
2 (10 d, 12 m) Pts demonstrated a significant improvement in
all domains. At 1 yr post CABG, pts
demonstrated almost equal HRQoL to the non-
cardiac population.
25 Krecki, 2010 CABG vs MED 55
52
Prospective, cross-
sectional
1 (12 m) CABG pts demonstrated significant
improvements in all domains, while MED pts
demonstrated significant improvements only in
pain and limitations due to emotional
problems.
26 Lie, 2009 CABG
Rehabilitation effects
185 Prospective, repeated
measures
2 (6 w, 6 m) Improvement in QoL level and NS differences
between groups were observed.
27 Martin, 2012 CABG + gender effect 495 Prospective, repeated
measures
1 (6 m) Improvement in all domains was observed.
Women significantly score lower at baseline
and 6 m posttreatment compared to men.
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28 Mathisen, 2005 CABG on vs off 120 Prospective, cross-
sectional
3 (3 m, 6 m, 12 m) QoL improved in both groups. NS differences
between groups were observed.
29 Merkouris, 2009 CABG + age effect 63 Prospective, repeated
measures
2 (4 m, 12 m) Pts demonstrated a significant improvement in
all domains except cognitive. Almost 1/3 of pts
reported cognitive decline.
At 12 months posttreatment, women scored
significantly lower than men.
30 Peric, 2010 CABG + gender effect 243 Prospective, repeated
measures
1 (6 m) Pts demonstrated improvement after
treatment. Women scored worse
preoperatively and postoperatively than men.
31 Pfaffenberger, 2010 CABG + anxiety, depression effect 54 Prospective, repeated
measures
2 (4 w, 3 m) Pts demonstrated significant improvement
after treatment Anxiety was a sig predictor for
scores in all QoL subdomains when the MacNew
is used as the outcome measure but only the
Mental Health domain when the SF-36 was
used. Depression was a significant predictor of
only mental health.
32 Pirraglia, 2003 CABG 590 Prospective, repeated
measures
1 (6 m) Pts demonstrated significant improvement
posttreatment.
33 Puskas, 2004 CABG on vs off 200 Prospective, repeated
measures
4 (4w, 6w, 6 m,
12 m)
Pts demonstrate significant improvement
posttreatment. NS differences between groups
were observed.
34 Rothenha¨usler, 2010 CABG + depression, PTSD 147 Prospective, repeated
measures
1 (6 m) Pts demonstrated significant improvement
posttreatment. Clinical depression and PTSD
were associated with lower levels of
improvement.
PCIZ percutaneous coronary intervention, CABGZ coronary bypass graft surgery, MEDZ pharmacotherapy, dZ days, wZweeks, mZmonths, ptsZ patients, NSZ nonsignificant,
PTSDZ posttraumatic stress disorder.
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Table 3 Central tendency and variability in the impact of coronary treatment on health-related quality of life.
Groups k N (pre/last follow-up) Hedge’s g (95% CI) Homogeneity of effect sizes
Fixed-effects
assumptions
Random-effects
assumptions
I2y t2z
Prior to sensitivity analysis
All studies (CR) 34 14375/12502 0.53 (0.51, 0.56) 0.59 (0.48, 0.69) 93.02 (91.21, 94.45) 0.08
PCI groups 14 8027/6857 0.43 (0.39, 0.46) 0.55 (0.40, 0.69) 93.01 (89.93, 95.15) 0.06
CABG groups 26 6348/5645 0.67 (0.64, 0.71) 0.60 (0.48, 0.72) 89.95 (86.59, 92.47) 0.08
MED groups 7 1617/1039 0.25 (0.18, 0.33) 0.25 (0.18, 0.33) 0.00 (0.00, 70.81) 0.00
After exclusions of outliers
All studies (CR) 19 5431/4656 0.54 (0.49, 0.57) 0.53 (0.47, 0.59) 29.92 (0.00, 59.85) 0.01
PCI groups 6 1955/1742 0.50 (0.44, 0.57) 0.48 (0.38, 0.59) 52.02 (0.00, 79.58) 0.01
CABG groups 15 3476/2914 0.54 (0.49, 0.59) 0.54 (0.47, 0.60) 25.42 (0.00, 0.45) 0.01
MED groups 3 390/290 0.32 (0.17,0.43) 0.32 (0.17,0.43) 0.00 (0.00, 89.60) 0.00
As I2 increases from 0, the presence of heterogeneity can be assumed (I2Z 25 defined minor heterogeneity, I2Z 50 defined moderate
heterogeneity, and I2Z 75 defined considerable heterogeneity). Presence of heterogeneity represented inconsistencies among indi-
vidual study results.
As t2 increases from 0, the presence of heterogeneity was assumed (t2> 1, considerable heterogeneity is present).
y based on precision.
z based on variance.
232 M.G. Takousi et al.PCI experienced a significantly greater improvement of
HRQoL over patients treated with medicines (MED) while
patients treated with PCI and CABG did not differ signifi-
cantly from each other (CABG>MED, mdZ 0.35, p< .005;
PCI>MED, mdZ 0.32, p< .05; CABG> PCI, mdZ 0.03,
pZ 0.72). Furthermore, when considering only the six
studies that included both PCI and CABG patients, the dif-
ference in improvement of HRQoL was also nonsignificant
(pZ 0.12).
Additionally, when the t2 index was used to detect the
level of heterogeneity in CR effect size, all studies seemed
to be homogeneous (t2Z 0.08), while when the I2 estimate
was used, a high level of heterogeneity (I2Z 93%) was
identified, suggesting that there were studies that should
be excluded as outliers.
In the examination of publications biases, Begg’s test
(zZ 0.03, pZ 0.98) and Egger’s test [tZ 4.98
(CIZ 0.25,0.61), pZ 0.19] results rejected the probability
of a significant publication bias.
Sensitivity analyses demonstrated that 15 studies should
be excluded as outliers. Table 3 and Figure 3 demonstrate
the number of studies retained. Even after their exclusion,
the combined effect size on HRQoL remained moderate for
both types of coronary revascularization and low for MED.
Overall, the mean difference became slightly lower but no
essential changes were detected, [F(2,32)Z10.42,
p< 0.001, CABG>MED, mdZ 0.27, p< 0.001; PCI>MED,
mdZ 0.20, p< 0.001, CABG> PCI, mdZ 0.07, pZ 0.28).
The forest plots (Figures 2 and 3) provide graphical
representations of effects sizes and CIs before and after
sensitivity analysis.
3.2. Moderator analysis
Including all 34 studies, three factors were associated with
the outcome: type of instrument, time (study duration) and
study quality. Multiple linear regression analysis of mean
difference weighted by the inverse variance demonstratedthat these moderators accounted for 96.5% of the outcome
variability. In fact, 13% of the variance was accounted for
by study quality [F(1,38)Z 6.69, p< 0.05], and 83.6% of the
variance could be attributed to type of instrument [F(7,31)
Z 109.98, p< 0.001], while time (study duration) accoun-
ted for a small but significant 1% of the variability [F(2,29)
Z 4.29, p< 0.05]. Specifically, analysis indicated that
these variables had larger effects in lower quality studies
(bZ2.69, t(33)Z2.36, pZ 0.025), in studies with
short-term follow-ups (bZ0.52, t(33)Z2.87,
pZ 0.007) and for disease-specific measures of HRQoL
(e.g., a larger effect for the disease-specific measure SAQ
)(bZ 20.83, t(33)Z 10.25, p< 0.001) than for the generic
SF-36 (bZ 11.91, t(33)Z 14.66, p< 0.001)).
When analyses were repeated with 19 studies (after
excluding outliers and poorer quality studies), the effect of
CR on HRQoL was still significant (Table 3). However, study
quality and study duration were no longer significant pre-
dictors, and the effect of HRQoL measurement type could
be not analyzed, as the majority of remaining studies (89%)
used the SF-36.
3.3. Subgroup analysis: Psychosocial vs Physical
domains
Subgroup analysis was conducted among the studies using
the SF-36 to assess HRQoL following CR to detect any dif-
ferences in the effect of CR on HRQoL within the psycho-
social and physical subdomains. In 21 studies (participant
nZ 5,232), findings revealed that patients reported
greater mean changes in the physical than the psychosocial
domains (ESZ 4.45, 95% CI, 3.93 to 5.20; p< 0.05).
However, the mean difference (md) between the phys-
ical and psychosocial domains were significant for CABG but
not PCI (Figure 4). Meta-regression analysis for the influ-
ence of potential moderators on the differences in CABG
effect sizes between the physical and psychosocial di-
mensions did not reveal any significant results.
Figure 2 Forest plot diagram showing the effect (hg) of CR within each study and the overall effect (kZ 34) after synthesis of
overall pooled effect. CIZ confidence interval. QZ 472.67, p< 0.005, I2Z93.02%.
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The present systematic review and meta-analysis identified
34 studies evaluating the effect of CR on improvements in
HRQoL to compare the effects of PCI and CABG on and to
identify factors moderating improvements in HRQoL
following CR.
PCI and CABG had moderate effects on improving HRQoL.
Both were significantly better than medication treatment
but did not differ from each other. These findings were
consistent with those of Blankenship et al. (2013)12 and
Jokinen et al. (2010),8 although these authors examined
only PCI and only CABG, respectively. The present study is
the first to examine both procedures simultaneously.
Regarding the duration of improved HRQoL, the effect
size was slightly greater at 12 months than at 36 or 48
months after CR (data not presented). This evidence is in
line with Blankenship et al.’s (2013)12 conclusions.
For both CR procedures, type of instrument used to
measure HRQoL and study quality were strong moderators
of the outcome. A discussion exists in the literature
regarding the instruments used in HRQoL research. In the
current paper, all studies used valid and reliable measures;
however, the majority used generic rather than disease-
specific measures. Studies using a disease-specificinstrument reported a greater effect size than studies using
generic measures. As there has been no consensus defini-
tion of QoL, results produced by various measurements may
vary significantly, as each instrument may include common
as well as different domains dependent upon the theoret-
ical framework used by the authors.66 While generic mea-
sures such as the SF-3667 are valid and reliable, some items
are likely to be less sensitive in detecting treatment ef-
fects68,69 for specific health conditions70 such as a coronary
revascularization.71 For example, in a rehabilitation pro-
gram, the results of a generic measure led to the conclusion
that the program did not improve QoL, while the results of
a disease-specific measurement did demonstrate significant
improvement.72
Neither age nor sex predicted HRQoL, although fewer
women than men had undergone CR in the included studies.
These findings are in line with Lansky et al.’s73,74 conclu-
sions that the seemingly worse outcomes in women may be
associated with higher risk profiles in women undergoing CR
and differences in mortality or health outcomes that have
been observed in some studies were related to risks factors
other than sex. In short, the findings of the present study
imply that neither age nor gender need be considered as
risk factors for lower HRQoL when treatment decisions for
coronary artery disease are made.
Figure 3 Forest plot diagram showing the effect (hg) of CR within each study and the overall effect (kZ 19) after excluding
outliers. CIZ confidence interval. QZ 40.35, p< 0.005, I2Z50.44%.
234 M.G. Takousi et al.Subgroups analyses showed a greater effect of CR on
physical functioning compared to psychosocial functioning
regardless of the procedure completed. However, the post
intervention mean score was similar for all subdomains of
HRQoL, suggesting that the beneficial effects in the psy-
chosocial domain may be due to patients demonstrating
greater dysfunction in physical rather than psychosocial
functioning prior to CR treatment. This implies that it is
vital that researchers consider pre-post scores and not just
compare the outcome (post) scores to draw conclusions, a
point also highlighted by Noyez et al. (2011).9
A large body of literature has been published addressing
the debate over the appropriate index for detecting het-
erogeneity in continuous data. Findings may change
dramatically depending on the index chosen. The findings in
the present study highlight this difference. When the t
index was used, homogeneity among studies was revealed
and type of instrument and female sex appeared to mod-
erate the effect of CR on improvements in HRQoL. How-
ever, when the I2 index was employed, 15 studies were
identified as outliers. With a subsequent decrease in het-
erogeneity after their exclusion, the effects of CABG and
PCI on improvement in HRQoL were maintained; however,
none of the variables examined had a significant moder-
ating effect. This highlights two basic issues: a) that stat-
isticians should focus on resolving this issue to allow
reviewers to detect genuine heterogeneity levels and b)
that findings from heterogeneous studies should beconsidered carefully before any recommendations are
made.
Several limitations are present in this study. First, only a
few studies examined the severity of angina prior to
treatment or provided data for complex coronary lesions.
As a result, these important variables were not included in
the analysis, raising questions about the precision of the
estimates for the effect of CR on HRQoL. Similarly, stressful
events, depression, personality traits,75 changes in life-
style, adherence to medical advice and other potentially
relevant factors were not considered because these were
not routinely measured in the studies reviewed. Second,
the majority of studies did not include control groups or
alternative treatments. Only 30% of the studies reviewed
presented comparisons between types of CR treatment,
which may lead reviewers to a misleading conclusions.
Studies using between-group designs generally demon-
strated lower effect sizes for HRQoL changes compared to
single group designs, a difference that may be due to the
manner in which effect size was estimated.26 Third,
although in many cases the type of medication patients
used wasn’t reported, when it was described, it differed
dramatically between treatment groups, suggesting meth-
odological biases that could not be controlled. Fourth, the
majority of studies had a follow-up period of less than 12
months, which may not be considered a sufficient period of
time to reflect the true long-term effects of a treatment.
Finally, the study’s overall sample and its potential effect
Figure 4 Forest plot diagram showing the mean difference (md) between physical and psychosocial domains per CR type; the
first part repots CABG md (p< 0.01) and the second PCI md (pZ 0.17). CIZ confidence interval.
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For instance, sex may be a moderator; however, relatively
few women were included in the studies reviewed. Thus,
results should be considered cautiously until more studies
with more women participants are published.
Measurement of HRQoL should be included in the routine
assessment of coronary patients in order to have a com-
plete picture of their condition and augment conclusions
about the effectiveness of treatment. Additionally,
cardiothoracic surgeons should pay attention to their pa-
tients’ psychosocial functioning and, if necessary, advise
them to seek professional guidance and support to maxi-
mize well-being.
Further high-quality research should be developed to
enable the scientific community to establish rigorous con-
clusions about factors that influence CR’s effect on pa-
tients’ HRQoL. Specifically, more RCTs and between-group
designs are needed to inform health care professionals
about the beneficial aspects of each treatment. More var-
iables should be included in each study to examine addi-
tional issues such as medical (e.g., angina), environmental/
behavioral (e.g., adherence to medication, diabetes man-
agement, obesity, and alcohol use) and psychological (e.g.,
stressful life events, emotional distress, and personality)
factors and identify relevant predictors. Studies should also
measure HRQoL at multiple time points and place a greater
emphasis on female recruitment to come to a more con-
crete conclusion regarding the issue of gender. More studiesusing disease-specific HRQoL instruments should also be
conducted, as the literature suggests disease-specific in-
struments may allow clearer and more accurate conclusions
than those derived from general instruments. Studies
should also report all HRQoL subdomains, not just totals,
and all relevant indices should be presented (e.g., pre-post
mean scores and p values) to avoid transformations and
calculations by reviewers that might lead to misleading
results.16
This meta-analysis provides empirical evidence of the
beneficial impact of coronary procedures on patients’
HRQoL. This information may help physicians not only to
justify their decision on which procedure to use but also to
inform patients about the pros and cons of each procedure
in terms of HRQoL. Determination of best practices in
research requires careful methodological consideration to
maximize study quality and produce trustworthy conclu-
sions. Despite the advancements that have been achieved,
considerable challenges and questions remain to be
addressed.
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